Supplemental financial information

9 Months Ended

Sep. 30, 2022

Supplemental financial information

Supplemental financial information

3.           Supplemental financial information

Cash, cash equivalents and restricted cash

Cash and cash equivalents consist of cash and, if applicable, highly liquid investments with an original maturity of three months or less when purchased. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the condensed statements of cash flows (in thousands).

	As of		As of
	September 30,		December 31,
	2022		2021
Cash and cash equivalents	$	66,584	$	106,124
Short-term restricted cash		179		197
Total cash, cash equivalents, and restricted cash shown in the statements of cash flows	$	66,763	$	106,321

Prepaid expenses and other current assets

Prepaid expenses and other current assets consist of the following (in thousands):

	As of		As of
	September 30,		December 31,
	2022		2021
Prepaid clinical	$	3,041	$	4,693
Prepaid insurance		1,529		1,122
Prepaid manufacturing costs		2,261		2,241
Other prepaid expenses and current assets		356		366
Total prepaid expenses and other current assets	$	7,187	$	8,422

Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):

	As of		As of
	September 30,		December 31,
	2022		2021
Employee-related expenses	$	867	$	2,567
Development costs and sponsored research		455		1,347
Clinical trials		131		810
Other		767		340
Total accrued expenses and other current liabilities	$	2,220	$	5,064